SAN FRANCISCO, Aug. 05, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended June 30, 2021. Second Quarter 2021 Financial Highlights Revenue was $81.3 million, a 59.8% […]
Financial
TransMedics Reports Second Quarter 2021 Financial Results
ANDOVER, Mass., Aug. 5, 2021 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2021. Recent Highlights Net revenue of $8.2 million in the second quarter of 2021, representing […]
Cytokinetics Reports Second Quarter 2021 Financial Results
Submission of NDA for Omecamtiv Mecarbil on Track to Occur in 2H 2021 Positive Results from REDWOOD-HCM Support Progression of Aficamten (CK-274) to Pivotal Phase 3 Trial in Patients with Obstructive Hypertrophic Cardiomyopathy Expected to Start in Q4 Pivotal Phase 3 Trial of Reldesemtiv in Patients with ALS Now Enrolling More […]
Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ended June 30, 2021 and provided key business updates. “I am […]
Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update
Conference call begins today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results […]
PLx Pharma Inc. Reports Second Quarter 2021 Results and Provides Business Update
–Walmart, Walgreens, Rite Aid, CVS and many other retailers placing VAZALORE on shelves later this month– –VAZALORE launch inventory manufactured and currently shipping to retailers across the country– SPARTA, N.J., Aug. 06, 2021 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused […]
Arena Reports Second Quarter Financial Results and Key Program Updates
– Phase 3 ELEVATE UC 12 trial reached full enrollment; topline data expected Q1 2022 with ELEVATE UC 52 – Liquidity position at ~$1.0 billion as of June 30, 2021 to support continued pipeline progress PARK CITY, Utah–(BUSINESS WIRE)–Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported […]
Quanterix Corporation Releases Operating Results for Second Quarter of 2021
Q2 GAAP revenue including Grant Revenue $25.4M; Q2 Non-GAAP revenue $24.4M, an increase of 86% over prior year; instrument placements up 71% BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months ending June 30, 2021. […]
Acceleron Reports Second Quarter 2021 Financial Results
– Highlighted ongoing and planned trials in rare pulmonary diseases and presented vision and strategy for long-term growth at June R&D Day – – Updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept in patients with pulmonary arterial hypertension (PAH) presented at the American Thoracic Society (ATS) 2021 […]
BD Announces Third Fiscal Quarter Results; Strong Base Growth Drives Better Performance In Quarter And Higher Guidance For Fiscal 2021
FRANKLIN LAKES, N.J., Aug. 5, 2021 /PRNewswire/ — Third fiscal quarter revenues of $4.9 billion grew 26.9% on a reported basis. On a currency-neutral basis, revenues increased 22.0%. BD’s COVID-19 testing revenues were $300 million, including BD Veritor™ Plus System revenues of $212 million. Third fiscal quarter GAAP diluted earnings per share (EPS) increased 77.3% year-over-year […]
Recent
Popular
- No commented posts yet